Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 continuous glucose monitor to automatically adjust insulin levels depending on blood glucose. It can be worn for up to 72 hours.
Users can control their pump and share data from an app if they have a...
Indian wellness startup K&L Wellness Technology scores $4M in seed funding
K&L Wellness Technology, a health technology startup in India, has bagged Rs 30 crore ($4 million) from angel investors to launch its wellness app.
According to a news report, the company seeks to redefine wellness through science-based personalised solutions.
K&L Wellness, also known as RESET Tech, provides...
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players. The meeting included presentation on studies covering a range of technologies, such as continuous glucose monitors, insulin pumps, apps, and other digital-backed management strategies.
Among the studies highlighted by the association was an...
Milpitas, California-based diabetes management device maker Bigfoot Biomedical has raised $37 million in Series B funding in a round co-led by funds from Janus Henderson Investors and Quadrant Capital Advisors. Additional participants included Cormorant Asset Management, Senvest Capital Inc., Senvest Management LLC, Visionnaire Ventures, JDRF T1D Fund, and T1D Exchange.
Bigfoot previously...
Heads of the FDA’s Center for Devices and Radiological Health (CDRH) recently penned a blog post describing their previous and ongoing efforts with closed-loop artificial pancreas manufacturers to ensure proper testing and validation of the devices.
In it, Courtney Lias, director of the Division of Chemistry and Toxicology Devices at CDRH, and Stayce Beck, chief of the Diabetes Diagnostics...
Indianapolis-based pharmaceutical Eli Lilly and Company announced this week that the first Type 1 diabetes patient has been dosed in a feasibility study of the company’s investigational Automated Insulin Delivery (AID) system.
The company’s hybrid closed-loop platform consists of an insulin pump with a dedicated controller for system inputs, a dosing algorithm, and a continuous glucose monitor (...
Efforts to build artificial pancreas (AP) systems under open protocols will get a boost from JDRF, a multinational group that funds Type 1 diabetes research and other programs. The organization has announced a new initiative to not only provide funds for these DIY and frequently reverse engineered projects, but will also provide the regulatory and liability guidance necessary for a public release...
Milpitas, California-based Bigfoot Biomedical, a diabetes management company working on their first product, announced an investment from the Juvenile Diabetes Research Foundation (JDRF)’s newly launched venture fund, T1D, focused on early stage companies working on type 1 diabetes. The terms of the investment were not disclosed, but Bigfoot previously raised $35.5 million.
The funding will be...
Boston-based nonprofit T1D Exchange has announced its intentions to make a multi-million dollar investment in automated insulin delivery technologies, the smart algorithms that serve as the bridge between CGMs and insulin pumps in the quest to create an artificial pancreas.
“Type 1 diabetes is a disease that, since the invention of artificial insulin back in 1921, still plagues us because...
